Isobutyl 1,3-dihydroxypropan-2-yl-carbamate | 1448705-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Isobutyl 1,3-dihydroxypropan-2-yl-carbamate
• 英文别名: 2-methylpropyl N-(1,3-dihydroxypropan-2-yl)carbamate
• CAS: 1448705-61-0
• 化学式: C₈H₁₇NO₄
• 分子量: 191.227
• InChiKey: FKNIGJNNGPRXIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  丝氨醇 、 氯甲酸异丁酯 生成 Isobutyl 1,3-dihydroxypropan-2-yl-carbamate
  参考文献：
  名称：

  Polycarbonates bearing pendant primary amines for medical applications

  摘要：

  一种抗微生物组合物包括一种阴离子药物和一种胺基聚合物，该聚合物包括公式（2）的第一重复单元： 其中a'为1或2的整数，b'为1或2的整数，每个R'是从氢，甲基，乙基和它们的组合中选择的独立单价基团。G'是选择自单键和包含至少一个碳的基团的双价连接基团。X-是带负电的对离子。药物和胺基聚合物通过非共价作用结合。

  公开号：

  US08926998B2

文献信息

• POLYCARBONATES BEARING PENDANT PRIMARY AMINES FOR MEDICAL APPLICATIONS
  申请人：Hedrick James L.

  公开号：US20140072607A1

  公开（公告）日：2014-03-13

  An antimicrobial composition comprises an anionic drug and an amine polymer comprising a first repeat unit of formula (2): wherein a′ is an integer equal to 1 or 2, b′ is an integer equal to 1 or 2, and each R′ is an independent monovalent radical selected from the group consisting of hydrogen, methyl, ethyl, and combinations thereof. G′ is a divalent linking group selected from the group consisting of a single bond and groups comprising at least one carbon. X − is a negatively charged counterion. The drug and the amine polymer are bound by noncovalent interactions.

  一种抗微生物组合物包括一种阴离子药物和一种胺聚合物，该胺聚合物包括具有以下式（2）的第一重复单元：其中a'是等于1或2的整数，b'是等于1或2的整数，每个R'是从氢、甲基、乙基和它们的组合中选择的独立单价基团。G'是从单键和包含至少一个碳的基团中选择的二价连接基团。X-是带负电的对离子。药物和胺聚合物通过非共价相互作用结合。
• [EN] POLYCARBONATES BEARING PENDANT PRIMARY AMINES FOR MEDICAL APPLICATIONS<br/>[FR] POLYCARBONATES PORTANT DES AMINES PRIMAIRES LATÉRALES POUR DES APPLICATIONS MÉDICALES
  申请人：IBM

  公开号：WO2014042924A1

  公开（公告）日：2014-03-20

  An antimicrobial composition comprises an anionic drug and an amine polymer comprising a first repeat unit of formula (2); wherein a' is an integer equal to 1 or 2, b' is an integer equal to 1 or 2, and each R' is an independent monovalent radical selected from the group consisting of hydrogen, methyl, ethyl, and combinations thereof. G' is a divalent linking group selected from the group consisting of a single bond and groups comprising at least one carbon. X¯ is a negatively charged counterion. The drug and the amine polymer are bound by noncovalent interactions.

  一种抗微生物组合物包括一种阴离子药物和一种胺聚合物，该胺聚合物包括公式（2）的第一重复单元；其中a'是等于1或2的整数，b'是等于1或2的整数，每个R'是从氢、甲基、乙基和它们的组合中选取的独立一价基团。G'是从单键和至少含有一个碳的基团中选取的二价连接基团。X¯是带负电的对离子。药物和胺聚合物通过非共价相互作用结合。
• Fatty acid cysteamine conjugates and their use as activators of autophagy
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：US10251845B2

  公开（公告）日：2019-04-09

  The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNGlE), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.

  本发明涉及(i)6-元杂芳基取代的脂肪酸胱胺共轭物、其组合物、用该化合物治疗涉及自噬失调的疾病的方法，如囊性纤维化、特发性肺纤维化（IPF）、神经退行性疾病、炎症性疾病、肝病、肌肉疾病、感染和免疫疾病，或(ii)治疗特发性肺纤维化的方法、线粒体疾病、Leigh 综合征、糖尿病和耳聋（DAD）、Leber 遗传性视神经病变、神经病-共济失调-视网膜色素变性和眼睑下垂（NARP）、肌神经源性胃肠道脑病（MNGlE）、或线粒体肌病-脑肌病-乳酸中毒中风样症状（MELAS），包括给患者服用脂肪酸半胱胺共轭物（4Z、7Z.10Z、13Z、16Z、19Z）-N-（2-巯基乙基）二十二碳-4,7,10,13,16,19-六烯酰胺或（5Z、8Z、11Z、14Z、17Z）-N-（2-巯基乙基）二十二碳-5,8,11,14,17-五烯酰胺。
• FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：US20170258741A1

  公开（公告）日：2017-09-14

  The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.
• US8926998B2
  申请人：——

  公开号：US8926998B2

  公开（公告）日：2015-01-06